Prevention of hepatocellular carcinoma in the Asia-Pacific region: Consensus statements

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 4, 2010, Pages 657-663

  Farrell, Geoff ^a  

^a The Australian National University   (Australia)

Author keywords

Hepatitis B vaccination; Hepatitis C virus; Surveillance for HCC; Universal precaution

Indexed keywords

HEPATITIS B VACCINE; PEGINTERFERON ALPHA; RIBAVIRIN;

ALCOHOL LIVER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; ERADICATION THERAPY; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL TRANSMISSION; VACCINATION; VIRUS TRANSMISSION;

EID: 77950136782     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06167.x     Document Type: Article

References (48)

1. Yuen MF, Hou J-L, Chutaputti A, on behalf of The Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma in the Asia-Pacific region. Hepatocellular carcinoma in the Asia Pacific Region. J. Gastroenterol. Hepatol. 2009 24 : 346 353.
2. Amarapurkar D, Han K-H, Chan JL-Y, Ueno Y. The Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2009 24 : 955 961.
3. Farrell GC, Fan JG. Prevention of hepatocellular carcinoma. In : Al Knawy B, Reddy KR, Bolondi L, eds. Hepatocellular Carcinoma: A Practical Approach. London : Informa Healthcare, 2009 36 61.
4. Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J. Gastroenterol. Hepatol. 2009 24 : 1352 1357.
5. Ueno Y, Sollano JD, Farrell GC. Prevention of hepatocellular carcinoma complicating hepatitis C. J. Gastroenterol. Hepatol. 2009 24 : 531 536.
6. Fan JG, Farrell GC. The Asia Pacific Working Party on Prevention of Hepatocellular Carcinoma in the Asia-Pacific region. Prevention of hepatocellular carcinoma in nonviral-related liver disease. J. Gastroenterol. Hepatol. 2009 24 : 712 719.
7. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. J. Gastroenterol. Hepatol. 2000 15 : 825 841.
8. Farrell GC. Consensus among consensus conferences on management of hepatitis C: what we knew then and are still sure about, what we are newly sure about, and what we still need to know. J. Gastroenterol. Hepatol. 2000 15 (Suppl E126 9.
9. Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005 25 : 472 489.
10. APASL Hepatitis C Working Party. APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus. J. Gastroenterol. Hepatol. 2007 22 : 615 633.
11. Kudo M, Okanoue T, Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007 72 (Suppl. 1 2 15.
12. Makuuchi M, Kokuda N, Aril S et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol. Res. 2008 38 : 37 51.
13. Farrell GC. Expanding horizons for the Journal: the role of the Journal of Gastroenterology and Hepatology Foundation. J. Gastroenterol. Hepatol. 2003 18 : 235 236.
14. Chen D-S. Toward elimination and eradication of hepatitis B. J. Gastroenterol. Hepatol. 2010 25 : 19 25.
15. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med. 1997 336 : 1855 1859.
16. Chang MH, You SL, Chen CJ et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst. 2009 101 : 1348 1355.
17. World Health Organization. WHO vaccine-preventable diseases: monitoring system, 2006 global summary. Geneva, Switzerland, 2000.
18. Alter MJ. Healthcare should not be a vehicle for transmission of hepatitis C. J. Hepatol. 2008 48 : 2 4.
19. Farrell GC. New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J. Gastroenterol. Hepatol. 2007 22 : 607 610.
20. Wiegand J. Newly acquired hepatitis C - many hurdles from diagnosis until treatment initiation. J. Gastroenterol. Hepatol. 2008 23 : 1782 1784.
21. Hershko C. Iron overload in Asia. Blood 2009 114 : 1 2.
22. Elmberg M, Hultcrantz R, Ekbom A et al. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 2003 125 : 1733 1741.
23. Allen KJ, Nisselle AE, Collins VR et al. Asymptomatic individuals at genetic risk of haemochromatosis take appropriate steps to prevent disease related to iron overload. Liver Int. 2008 28 : 363 369.
24. Hao W, Su Z, Liu B et al. Drinking and drinking patterns and health status in the general population of five areas of China. Alcohol & Alcoholism 2004 39 : 43 52.
25. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004 127 : S87 96.
26. Day CP. Treatment of alcoholic liver disease. Liver Transpl. 2007 13 (Suppl. 2 S69 75.
27. El-Serag HM, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 132 : 2557 2576.
28. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004 127 : S72 8.
29. Huo TI, Wu JC, Lee SD. Are alcohol, tobacco and obesity genuine risk factors for hepatocellular carcinoma? J. Hepatol. 2005 42 : 941 943.
30. Caldwell SH, Crespo DM, Kang HS et al. Obesity and hepatocellular carcinoma. Gastroenterology 2004 127 : S97 S103.
31. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: a systemic review and meta-analysis of prospective observational studies. Lancet 2008 371 : 569 578.
32. Jackson H, Solaymani-Dodaran M, Cart TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 2007 46 : 1131 1137.
33. Sulkowski M. Hepatocellular carcinoma in HIV-infected patients comes of age: the convergence of epidemiology and treatment effectiveness. J. Hepatol. 2009 50 : 655 658.
34. Amin J, Dore GJ, O'Connell DL et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. Lancet 2006 368 : 938 945.
35. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br. J. Cancer 2007 96 : 1127 1134.
36. Lau GK, Piratvisuth T, Luo KC et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005 352 : 2682 2695.
37. Liaw YF, Sung JJ, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004 351 : 1521 1531.
38. Sung JJY, Tsoi KKF, Wong VWS, Li KCT, Chan HLY, Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2008 28 : 1067 1077.
39. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 : 65 73.
40. Farrell GC. Hepatocellular carcinoma after sustained response to interferon in non-cirrhotic hepatitis C: flaws in the cure, or clues to the flaw? J. Gastroenterol. Hepatol. 1999 14 : 833 837.
41. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann. Intern. Med. 1999 131 : 174 181.
42. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999 29 : 1124 1130.
43. Arase Y, Ikeda K, Suzuki F et al. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J. Med. Virol. 2007 79 : 1485 1490.
44. Yu M-L, Chuang W-L. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol. 2009 24 : 336 345.
45. Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 2008 359 : 2429 2441.
46. Clavien PA. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection? Ann. Surg. 2007 245 : 843 845.
47. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J. Hepatol. 2009 50 : 227 242.
48. American Association for the Study of Liver Diseases (AASLD). Guidelines (recently updated). Cited 26 October 2009. Available from URL: http://www.aasld.org/Pages/Default.aspx